Oncology Surgery Department (Thyroid Surgery)

The Department of Surgical Oncology (Thyroid Surgery) of Hangzhou First People’s Hospital Affiliated with Westlake University School of Medicine is a key medical discipline in Hangzhou, the Hangzhou Thyroid Disease Diagnosis and Treatment Center, a unit serving as a deputy chair member of the Thyroid Disease Branch of the China Health Care International Exchange Promotion Association, and a unit serving as a deputy chair member of the Surgical Oncology Branch of the Zhejiang Medical Association. The department conducts clinical diagnosis and treatment as well as basic research on thyroid (parathyroid) tumors and breast tumors. It promotes a comprehensive diagnosis and treatment model centered on surgery and integrating medical imaging, nuclear medicine, molecular biology, medical oncology, radiation oncology, and other disciplines. It implements personalized precision diagnosis and treatment; uses artificial intelligence to distinguish benign from malignant thyroid nodules and to differentiate the malignancy levels of thyroid cancers; uses CT virtual navigation technology to detect occult tumor metastases; uses nerve-monitoring technology to protect postoperative voice function after thyroid surgery; and uses open, endoscopic (transoral, axillary, trans-areolar, and other approaches), and Da Vinci surgery to achieve radical, functional, and cosmetic tumor treatment. The department has led more than 30 research projects funded by the National Natural Science Foundation of China and at provincial and ministerial levels, received more than 10 scientific and technological awards, including the Second Prize of the Zhejiang Provincial Science and Technology Progress Award, published more than 100 research papers in authoritative domestic and international journals, and led or participated in the formulation of more than 10 national expert consensuses, guidelines, and standards for tumor diagnosis and treatment. It holds the “Hangzhou Thyroid Cancer Forum” every year and has broad influence in China. In 2025, at the World Thyroid Cancer Congress, it reported several latest research achievements, including thyroid cancer risk stratification, thereby making China’s voice heard internationally.